212 results
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
outstanding: 289,057,198
Financial Outlook and Path to Profitability Clear strategy to build our business, advance our portfolio, and achieve
S-3ASR
FOLD
Amicus Therapeutics Inc
8 Nov 23
Automatic shelf registration
5:25pm
relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives
8-K
EX-99.2
y2jvzs4v3yy0mf6iox3
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
1kehutlz
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
EX-99.2
6b1mdw byea9i6
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.2
q8eo4t6haakwn 25
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
j9zz0wnejqg0ldcf7
16 Nov 22
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
7:01am
8-K
EX-99.2
0u98w
7 Nov 22
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
2:31pm
424B5
qo4j hqvc9bdxyjr5
7 Nov 22
Prospectus supplement for primary offering
7:11am
8-K
EX-99.2
ddk1p0bw rd
7 Nov 22
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
xz8l s3fvvhsyyq
14 Sep 22
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
7:00am